You are here

FDA Gives “Thumbs Down” to Calcifediol (Rayaldee) for Hyperparathyroidism

Agency cites manufacturing concerns

The FDA has issued a complete response letter (CRL) in reply to a new drug application (NDA) for calcifediol modified-release capsules (Rayaldee, Opko Health) as a treatment for secondary hyperparathyroidism (SHPT) in patients with stage-3 or -4 chronic kidney disease (CKD) and vitamin D insufficiency.

The FDA indicated that observations of deficiencies at a third-party contract manufacturer were issued in March 2016 as a result of an FDA field inspection. The observations were not specific to the manufacturing of calcifediol. The CRL did not cite any safety, efficacy, or labeling issues with regard to calcifediol, nor did it request any additional studies to be conducted prior to the FDA’s final decision on approval. In the CRL, the FDA reconfirmed its acceptance of the proprietary name Rayaldee.

The NDA for calcifediol was accepted in July 2015.

Calcifediol is an oral vitamin D prohormone treatment developed for SHPT in patients with stage-3 or -4 CKD and vitamin D insufficiency. It has a proprietary modified-release formulation designed to gradually raise serum total 25-hydroxyvitamin D (prohormone) concentrations to targeted levels (at least 30 ng/mL) while avoiding upregulation of cytochrome P450-24A1, an enzyme that interferes with the desired parathyroid hormone-lowering effect. The gradual elevation of serum total 25-hydroxyvitamin D is intended to prevent excessive elevation of serum calcium and related vascular and renal calcification.

Sources: Opko Health; March 30, 2016; and Opko Health; July 28, 2015.

More Headlines

Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
National Statistics Report Factors In Race, Ethnicity for the First Time
FDA Prioritizing Review of ARB Applications to Help Mitigate Drug Shortage
California Woman Claimed Asbestos in Talc-Based Powder Caused Her Mesothelioma
Synergistic Effects Seen When Combined With Cisplatin in Mice
For Locally Advanced or Metastatic Triple-Negative Type Only